IDENTIFICATION OF MOLECULAR MARKERS AND MICRORNAS ASSOCIATED WITH DISEASE SEVERITY IN CHRONIC KIDNEY DISEASE PATIENTS WITH LIVER DYSFUNCTION
Genetics and Molecular Research · 02.06.2026
DOI: 10.4238/cgnbxk79 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics and Molecular Research, online erschienen am 02.06.2026. Verfasst von Dr. Boya Koushik Kumar und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) is a progressive and irreversible disorder frequently associated with liver dysfunction, resulting in increased morbidity and poor clinical outcomes. Conventional renal and hepatic biomarkers may not adequately reflect the molecular mechanisms underlying disease progression. Molecular biomarkers and microRNAs (miRNAs) have emerged as promising tools for evaluating renal injury, fibrosis, inflammation, and disease severity in CKD patients with concomitant liver dysfunction.
Methods
This experimental cross-sectional study was conducted in the Department of General Medicine, Dr. D. Y. Patil Medical College, Hospital and Research Institute, Kolhapur. Sixty adult CKD patients with liver dysfunction and twenty healthy controls were enrolled. Clinical, hematological, renal, and liver function parameters were assessed. Plasma levels of Kidney Injury Molecule-1 (KIM-1), Neutrophil Gelatinase-Associated Lipocalin (NGAL), and Matrix Metalloproteinase-9 (MMP-9) were measured. Expression of miR-21, miR-29, and miR-122 was quantified using quantitative real-time PCR. Biomarker levels were compared between groups and across CKD stages, and correlations with estimated glomerular filtration rate (eGFR), serum creatinine, blood urea, and liver function tests were analyzed.
Results
CKD patients with liver dysfunction demonstrated significantly elevated KIM-1 (417.27 vs. 209.08 pg/mL), NGAL (447.27 vs. 210.05 pg/mL), MMP-9 (2311.52 vs. 1632.56 pg/mL), and miR-21 expression (2.71 vs. 1.29-fold), while miR-29 expression was significantly reduced (0.38 vs. 1.09-fold) compared with controls (all p
Zitieren
APA
Kumar, D. B. K., Nagaonkar, D. V., Jotkar, D. S. K., & Khyalappa, D. R. J. (2026). IDENTIFICATION OF MOLECULAR MARKERS AND MICRORNAS ASSOCIATED WITH DISEASE SEVERITY IN CHRONIC KIDNEY DISEASE PATIENTS WITH LIVER DYSFUNCTION. Genetics and Molecular Research. https://doi.org/10.4238/cgnbxk79
Vancouver
Kumar DBK, Nagaonkar DV, Jotkar DSK, Khyalappa DRJ. IDENTIFICATION OF MOLECULAR MARKERS AND MICRORNAS ASSOCIATED WITH DISEASE SEVERITY IN CHRONIC KIDNEY DISEASE PATIENTS WITH LIVER DYSFUNCTION. Genetics and Molecular Research. 2026. doi:10.4238/cgnbxk79
BibTeX
@article{Kumar2026,
author = {Kumar, Dr. Boya Koushik and Nagaonkar, Dr. Vijay and Jotkar, Dr. Sushama K and Khyalappa, Dr. Rajesh J.},
title = {IDENTIFICATION OF MOLECULAR MARKERS AND MICRORNAS ASSOCIATED WITH DISEASE SEVERITY IN CHRONIC KIDNEY DISEASE PATIENTS WITH LIVER DYSFUNCTION},
journal = {Genetics and Molecular Research},
year = {2026},
doi = {10.4238/cgnbxk79}
}
EUVIMED